European regulators have recommended changes to the product label for GlaxoSmithKline's (GSK.L) pandemic flu vaccine Pandemrix to highlight the potential risk of narcolepsy in children or adolescents. The decision is based on preliminary results of studies from Finland, Sweden and France suggesting a possible link between the vaccine and the rare sleeping disorder. The move does not apply to adults...UPDATE: Press Release from the European Medicines Agency.
Friday, April 15, 2011
From Reuters today:
Posted by Meryl Nass, M.D. at 9:50 AM